Shionogi Of Japan, GSK Of U.K. Report Good Results From HIV/AIDS Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi reports strong encouragement from Phase II trials for its drug to treat HIV/AIDS. Shionogi is testing the drug as part of a joint development deal with GlaxoSmithKline of the United Kingdom. Their study indicated the S/GSL1349572 drug lowered the virus to levels that could not be detected in 70 percent of the participants. After 10 days, none of the South Africa patients displayed drug resistance, the study said. The drug relies on blocking the integrase enzyme. (Click here for more
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.